Furthermore, they also identified that the percentage of TIM-3 positivity was significantly higher on peripheral CD4+ and CD8+ T cells from glioma patients overall (seven out of thirty were glioblastoma patients) compared to CD4+ and CD8+ T cells from healthy controls [68]. This evidence concerns the gene CD4 and glioblastoma.